Why Us?
At Par Health, we believe great healthcare is built on getting the essentials right. We’re looking for passionate, talented individuals who share our commitment to improving lives. With a global workforce, we lead with pride and purpose—prioritizing quality and safety while fostering a culture of continuous improvement, accountability, and teamwork. Elevating the Essentials isn’t just our tagline, it’s the higher standard we live by every day.
The Director of Controlled Substances Compliance reports to the Vice President, Head Litigation and Corporate Counsel, and leads Par Health’s (the “Company’s”) Drug Enforcement Administration (DEA) compliance function, which is a critical part of the continued success of the business. This position is also at the center of the Company’s industry-leading Anti-Diversion Program, which focuses on addressing the issues of diversion and abuse of controlled substances products. The position requires in-depth knowledge of DEA regulations and the ability to interact in a professional manner with Company leadership, personnel from the DEA Field Offices and DEA Headquarters, and representatives from large wholesale and retail chain customers.
The Director of Controlled Substances Compliance is responsible for synchronizing controlled substances reporting, quota requests, quota tracking, DEA audit preparedness across sites (St. Louis, MO; Fenton, MO; Hobart, NY; Webster Groves, MO; and Rochester, MI) as well as interacting with various functions across the business including Commercial, Supply Chain, Customer Service, Manufacturing, Quality, and Trade Compliance.
As a subject matter expert on DEA regulations, this position is ultimately accountable for the Company’s systems and procedures to maintain the required closed system of narcotics distribution including: DEA and State registration license renewals, quota consumption monitoring, quota request submissions, DEA ARCOS reporting and State-mandated reporting, comprehensive recordkeeping, complete and accurate year end physical inventory counts, inventory reconciliation, discrepancy investigations, DEA narcotic raw material reports and DEA Close of Business Reports.
This position has primary leadership responsibilities for all DEA and State agency controlled substances-related inspections. Additionally, the Director of Controlled Substances Compliance is the primary contact for DEA Washington, DC when escalation is required for issues relating to quota, import/export permits and certificates of registration.
The Director of Controlled Substances Compliance participates in customer visits and delivers presentations covering the Company’s Quota and Anti-Diversion Programs.
ESSENTIAL FUNCTIONS:
MINIMUM REQUIREMENTS:
Education:
Bachelor’s degree preferred or equivalent relevant experience
Experience:
Skills/Qualifications:
RELATIONSHIPS WITH OTHERS:
WORKING CONDITIONS:
Office based location in Hazelwood, MO with occasional travel to Company facilities in Missouri, New York, and Michigan, as well as to Washington, DC and customer sites throughout the US.
DISCLAIMER:
The above statements are intended to describe the general nature and level of work being performed by employees assigned to this classification. They are not intended to be construed as an exhaustive list of all responsibilities, duties and skills required of employees assigned to this position.
EEO Statement:
We comply with all applicable federal, state, and local laws prohibiting discrimination and harassment, and provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetic information, or any other classification protected by federal, state or local law. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.

Endo combined with Mallinckrodt Pharmaceuticals in 2025 to better serve customers and improve outcomes for the patients we support.
From this union, we established two focused, standalone companies:
– Keenova Therapeutics, a branded therapeutics business
– Par Health, a generics and sterile injectables business
To learn more, follow Keenova and Par Health on LinkedIn and visit keenova.com and parhealth.com.